PressMay 16, 2023 FSD Pharma Announces Receipt of Court Action and Update on Spin-Out and Distribution
PressMay 16, 2023 Incannex Company Presentation – Presentation of Psychennex, Psychedelic Therapies Subsidiary Company
PressMay 16, 2023 PharmAla Biotech and Shaman Pharma Granted First Ever Special Access Program Authorization for MDMA
PressMay 16, 2023 FILAMENT HEALTH ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
PressMay 12, 2023 Silo Pharma’s SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease
PressMay 12, 2023 FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort
PressMay 12, 2023 Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder
PressMay 11, 2023 GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights
PressMay 11, 2023 COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights
PressMay 11, 2023 atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates
PressMay 11, 2023 Sunstone Therapies to present data on the long-term efficacy of psilocybin therapy in cancer patients with major depressive disorder (MDD) at the ASCO 2023 Annual Meeting
PressMay 11, 2023 Clearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces Granting of Stock and Warrants
PressMay 9, 2023 Silo Pharma’s SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease
PressMay 8, 2023 Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam
PressMay 8, 2023 MIND CURE AND LNG ENERGY GROUP ENTER INTO ARRANGEMENT AGREEMENT WITH RESPECT TO PREVIOUSLY ANNOUNCED BUSINESS COMBINATION TRANSACTION
PressMay 5, 2023 First Patient Dosed in Beckley Psytech’s Phase IIa Study of BPL-003 for Treatment Resistant Depression
PressMay 4, 2023 Optimi Health Announces CAD$1.2 Million GMP Psilocybin Supply Agreement for Clinical Research and Development
PressMay 4, 2023 COMPASS Pathways plc to announce first quarter 2023 financial results on 11 May 2023
